Literature DB >> 22011503

Natamycin in the treatment of keratomycosis: correlation of treatment outcome and in vitro susceptibility of fungal isolates.

Linu Pradhan1, Savitri Sharma, Suma Nalamada, Srikant K Sahu, Sujata Das, Prashant Garg.   

Abstract

In this study, 60 fungal isolates from 60 patients with fungal keratitis were tested in vitro for their susceptibility to natamycin and the mean minimum inhibitory concentrations of natamycin (MICn) were correlated with clinical outcome. The mean MICn for various groups of fungi from patients with either early (<10 days) or late (≥ 10 days) presentation was correlated with the outcome. Aspergillus flavus showed resistance to natamycin with a high mean MICn (>16 μg/ml). While the clinical response in all patients with early A. flavus keratitis was good it was poor in late cases (5/8 patients, 62.5%). Fusarium species, Acremonium species and dematiaceous fungi were sensitive with low mean MICn (Fusarium: 5.7-7.2 μg/ml, Acremonium: 5.7-6.8 μg/ml, dematiaceous: (1.6-4 μg/ml). However, 46.6% (7/15) patients in Fusarium and 57.1% (4/7) in Acremonium group needed keratoplasty. We conclude that despite susceptibility of most fungal species causing keratitis to natamycin, the treatment outcome is poor in advanced fungal keratitis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22011503      PMCID: PMC3214429          DOI: 10.4103/0301-4738.86328

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


Keratomycosis is the leading cause of ocular morbidity throughout the world and fungi are the principal etiological agents of corneal ulceration in India.[1-3] Different classes of antifungal drugs used for treatment of fungal keratitis include polyenes, triazoles, and echinocandins.[2] Of these, natamycin is the mainstay of treatment and is widely used in India. However, treatment outcome in fungal ulcers tends to be poorer compared to bacterial and Acanthamoeba keratitis.[13] In the non-ophthalmic literature a fairly wide range of antifungal susceptibility test results are available for prediction of clinical outcome in fungal infections.[4] In contrast, such information is lacking in keratomycosis. Only a limited number of antifungal susceptibility testing of ocular isolates has been reported[56] and except for one none have correlated with response to treatment in the patients.[6] In the present study 60 fungal isolates from 60 patients with fungal keratitis were tested in vitro for their susceptibility to natamycin eye drop and the mean minimum inhibitory concentrations (MIC) were correlated with the clinical outcome with topical 5% natamycin eye drops.

Materials and Methods

In this prospective, non randomized interventional study corneal scrapings from patients with microbial keratitis were processed and interpreted as per our institutional protocol.[3] Consent was obtained from all patients. Taking appropriate laboratory precautions all significant fungal growth were tested for their susceptibility to natamycin eye drop (Sun pharmaceutical Ind. Ltd, Mumbai, India) by the previously described microbroth dilution method.[7] All patients received intensive treatment with one hourly 5% natamycin eye drops round the clock in the affected eye for the first three days with subsequent modification as per response. Twenty five patients were given oral ketoconazole (200 mg twice daily) and two patients received oral fluconazole (150 mg twice daily). Clinical outcome at one month was considered for analysis. An ulcer was defined either completely healed or resolving (reduction in infiltrate size) or worsened (increase in infiltrate size, keratoplasty). Since the treatment outcome is known to be affected by severity of disease the mean MIC of natamycin for different groups of fungi for patients presenting with in 10 days (early onset) or after 10 days (late onset) of symptoms were correlated with the clinical outcome.[8]

Results

Fungal species wise comparison of mean MIC of natamycin with treatment outcome was made among the patients with early and late onset disease [Table 1]. A. flavus (n = 13) showed the highest mean MIC (early-17.7 μg/ml, late-20.0 μg/ml) suggesting lowest susceptibility to natamycin. Excluding the patients lost to follow up five out of 6 patients (83.3%) had poor clinical response in the late group (A. flavus) while none had worsened in the early group (A. flavus). A. fumigatus, in contrast, showed high susceptibility to natamycin in vitro with mean MIC of 4.12 μg/ml. The clinical outcome, however, was poor in the cases that presented late. MIC of natamycin was relatively low for Fusarium species with mean MIC between 5.7-8 μg/ml. Nevertheless, 7 out of 14 patients (50.0%, 1 lost to follow up) needed penetrating keratoplasty to control the infection suggesting poor clinical response to natamycin. Among the dematiaceous fungi, Curvularia species were isolated in four patients and natamycin showed low MIC against these isolates (mean MIC in early - 1.6 μg/ml, late - 2 μg/ml).
Table 1

Treatment outcome of patients with early (<10 days) and late (>10 days) onset of fungal keratitis caused by various groups of fungi and their correlation with MIC of natamycin

Treatment outcome of patients with early (<10 days) and late (>10 days) onset of fungal keratitis caused by various groups of fungi and their correlation with MIC of natamycin

Discussion

A notable publication by Prajna et al., has convincingly shown that eye drop preparations are an alternative to pharmaceutical grade natamycin (not available to most laboratories) for testing antifungal susceptibility.[7] This study applied the same technique to evaluate the MIC of natamycin against various isolates of fungi from corneal scrapings of patients with mycotic keratitis. Owing to a small sample size in various groups of fungi, the mean MIC[9] was considered for comparison rather than MIC90 or MIC50. Susceptibility breakpoints for natamycin have not been described so far in CLSI guidelines, however, MIC of 16 μg/ml or less is considered to indicate susceptibility of a fungal isolate.[7] This study reassuringly found low MIC of natamycin (≤16 μg/ml) in all fungal isolates tested except A. flavus. A. flavus associated with keratitis is a particularly virulent fungus and is known to be associated with poor outcome in keratomycosis.[8] Apart from the toxins,[10] its perilous status is compounded by its resistance to natamycin. It is not known whether this resistance is inherent to this species. All isolates of Fusarium species were sensitive to natamycin but that did not translate to good clinical outcome in patients with Fusarium keratitis irrespective of early or late presentation. This probably points to the well known fact of poor penetration of natamycin especially in presence of advanced fungal keratitis affecting deeper layers of the cornea. Most encouraging results were obtained with respect to dematiaceous fungi [Table 1]. Scedosporium apiospermum and Bipolaris species showed susceptibility to natamycin with low MIC as well as favourable response to treatment with natamycin. However, both patients with Exerohilum species infection had presented late and showed poor response. Good treatment outcome in keratitis caused by dematiaceous fungi can be attributed to low virulence of dematiaceous fungi and their tendency to remain in the superficial tissues of cornea for long.[11] This study shows that a low MIC of natamycin (susceptible fungi) was not always associated with good treatment outcome with natamycin in fungal keratitis. As is well known, a large number of factors affect success or failure of medical therapy of fungal keratitis, severity of infection being one of them.[8] Our treatment protocol for fungal keratitis includes systemic antifungals for patients with the ulcer more than 6 mm in diameter or extending beyond anterior half of the stroma or when there is hypopyon. Systemic antifungal therapy given in some of the patients in this study may be a confounding factor which was not analyzed and is one of the limitations of this study. Using logistic regression Shapiro et al., showed that a two fold increase in MIC results in 47% reduction in the odds of healing.[6] However, results of the present study suggest that such a conclusion may be too simplistic and a considerably large study addressing multiple factors would be necessary to determine the effect of various parameters on the treatment outcome of fungal keratitis. Despite the limitation of small sample size in each group of fungi and statistically non significant results, we believe that our results are clinically significant. The susceptibility of A. flavus to natamycin is particularly poor and patients with this infection may require aggressive treatment, closer follow up and early surgical intervention. In vitro susceptibility of most other species of fungi, such as Fusarium spp., A. fumigatus, Acremonium spp., S. apiospermum, Bipolaris spp., Curvularia spp. etc., to natamycin may account for good clinical response when the intervention occurs early in the disease.
  11 in total

1.  Has antifungal susceptibility testing come of age?

Authors:  John H Rex; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2002-09-24       Impact factor: 9.079

2.  In vitro natamycin susceptibility of ocular isolates of Fusarium and Aspergillus species: comparison of commercially formulated natamycin eye drops to pharmaceutical-grade powder.

Authors:  P Lalitha; R Vijaykumar; N V Prajna; A W Fothergill
Journal:  J Clin Microbiol       Date:  2008-08-13       Impact factor: 5.948

3.  Susceptibility testing and clinical outcome in fungal keratitis.

Authors:  Brett L Shapiro; Prajna Lalitha; Allison R Loh; Annette W Fothergill; Namperumalsamy V Prajna; Muthiah Srinivasan; Amit Kabra; Jaya Chidambaram; Nisha R Acharya; Thomas M Lietman
Journal:  Br J Ophthalmol       Date:  2010-03       Impact factor: 4.638

Review 4.  Current perspectives on ophthalmic mycoses.

Authors:  Philip A Thomas
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

5.  Keratitis due to Aspergillus flavus: clinical profile, molecular identification of fungal strains and detection of aflatoxin production.

Authors:  George Leema; Jayaraman Kaliamurthy; Pitchairaj Geraldine; Philip A Thomas
Journal:  Mol Vis       Date:  2010-05-11       Impact factor: 2.367

6.  Genotypic and phenotypic properties of Candida parapsilosis sensu strictu strains isolated from different geographic regions and body sites.

Authors:  Arianna Tavanti; Lambert A M Hensgens; Selene Mogavero; László Majoros; Sonia Senesi; Mario Campa
Journal:  BMC Microbiol       Date:  2010-07-28       Impact factor: 3.605

Review 7.  The epidemiological features and laboratory results of fungal keratitis: a 10-year review at a referral eye care center in South India.

Authors:  Usha Gopinathan; Prashant Garg; Merle Fernandes; Savitri Sharma; Sreedharan Athmanathan; Gullapalli N Rao
Journal:  Cornea       Date:  2002-08       Impact factor: 2.651

Review 8.  Fungal keratitis.

Authors:  M Srinivasan
Journal:  Curr Opin Ophthalmol       Date:  2004-08       Impact factor: 3.761

9.  Evaluation of agent and host factors in progression of mycotic keratitis: A histologic and microbiologic study of 167 corneal buttons.

Authors:  Geeta Kashyap Vemuganti; Prashant Garg; Usha Gopinathan; Thomas J Naduvilath; Rajesh K John; Rajeev Buddi; Gullapalli N Rao
Journal:  Ophthalmology       Date:  2002-08       Impact factor: 12.079

10.  Review of epidemiological features, microbiological diagnosis and treatment outcome of microbial keratitis: experience of over a decade.

Authors:  Usha Gopinathan; Savitri Sharma; Prashant Garg; Gullapalli N Rao
Journal:  Indian J Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 1.848

View more
  16 in total

1.  Natamycin and Azithromycin Are Synergistic In Vitro against Ocular Pathogenic Aspergillus flavus Species Complex and Fusarium solani Species Complex Isolates.

Authors:  Haoyi Guo; Lutan Zhou; Yi He; Chuanwen Gao; Lei Han; Yan Xu
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

2.  Natamycin and Voriconazole Exhibit Synergistic Interactions with Nonantifungal Ophthalmic Agents against Fusarium Species Ocular Isolates.

Authors:  Michael E Zegans; Robert A Cramer; Christiaan A Rees; Ruina Bao
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

3.  In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial.

Authors:  Prajna Lalitha; Catherine Q Sun; N Venkatesh Prajna; Rajarathinam Karpagam; Manoharan Geetha; Kieran S O'Brien; Vicky Cevallos; Stephen D McLeod; Nisha R Acharya; Thomas M Lietman
Journal:  Am J Ophthalmol       Date:  2013-10-22       Impact factor: 5.258

4.  Fusarium keratitis: genotyping, in vitro susceptibility and clinical outcomes.

Authors:  Rafael A Oechsler; Michael R Feilmeier; Darlene Miller; Wei Shi; Ana Luisa Hofling-Lima; Eduardo C Alfonso
Journal:  Cornea       Date:  2013-05       Impact factor: 2.651

5.  Effect of voriconazole and ultraviolet-A combination therapy compared to voriconazole single treatment on Fusarium solani fungal keratitis.

Authors:  Kyoung Sub Choi; Sang Chul Yoon; Tyler Hyung Taek Rim; Soo Jung Han; Eun-Do Kim; Kyoung Yul Seo
Journal:  J Ocul Pharmacol Ther       Date:  2014-04-11       Impact factor: 2.671

6.  Argon laser photocoagulation versus intrastromal voriconazole injection in treatment of mycotic keratitis.

Authors:  Mohammad M Khater; Mohammad S El-Shorbagy; Adel A Selima
Journal:  Int J Ophthalmol       Date:  2016-02-18       Impact factor: 1.779

7.  Clinical and Mycological Features of Fungal Keratitis: A Retrospective Single-Center Study (2012-2018)

Authors:  İbrahim İnan Harbiyeli; Elif Erdem; Nuhkan Görkemli; Astan İbayev; Hazal Kandemir; Arbil Açıkalın; Macit İlkit; Meltem Yağmur
Journal:  Turk J Ophthalmol       Date:  2022-04-28

8.  Fusarium keratitis in Brazil: genotyping, in vitro susceptibilities, and clinical outcomes.

Authors:  Rafael A Oechsler; Tiago M Yamanaka; Paulo Jm Bispo; Juliana Sartori; Maria Cecilia Zorat Yu; Analy Salles A Melo; Darlene Miller; Ana Luisa Hofling-Lima
Journal:  Clin Ophthalmol       Date:  2013-08-29

9.  Staining with methylthioninium chloride for the diagnosis of fungal keratitis.

Authors:  Lan Lan; Feng-Yun Wang; Guangwei Zeng
Journal:  Exp Ther Med       Date:  2013-09-05       Impact factor: 2.447

10.  Microscopic evaluation, molecular identification, antifungal susceptibility, and clinical outcomes in fusarium, Aspergillus and, dematiaceous keratitis.

Authors:  Devarshi U Gajjar; Anuradha K Pal; Bharat K Ghodadra; Abhay R Vasavada
Journal:  Biomed Res Int       Date:  2013-10-24       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.